Speaker Profile
M.D., Executive Chairman & Co-Founder, Allogene Tx
Biography
Arie S. Belldegrun is a trailblazing urologiconcologistturnedbiotech entrepreneur whose companybuilding spreefrom Agensys and Cougar to Kite Pharmahelped usher in the first FDAapproved CART therapy and led to Kites $11.9 billion sale to Gilead Sciences.After that landmark exit, he cofounded Allogene Therapeutics and still serves as its Executive Chairman, steering the next wave of offtheshelf (allogeneic) CART cell products toward the clinic.Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the realestate venture Breakthrough Properties, nurturing a constellation of startups that translate science into patient impact.Over three decades on UCLAs faculty, he has authored 500plus scientific papers, mentored a generation of physicianscientists, and kept patient benefit at the center of every dealcementing his reputation as one of precision medicines most influential builders.
Talk
AI and Data Sciences Showcase:
OncoNex
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia University
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
CAR-T Cell Therapies: Strategies in Mitigating Challenges in Solid Tumor Delivery
• Chair: David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Royal Marsden
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• David Chang, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
TCR-Based Cell Therapies: New Targets and Clinical Advances
• Chair: Diwakar Davar, UPMC
• Lauren Harshman, Clasp Therapeutics
• Cassian Yee, MD Anderson Cancer Center
Gene Editing & Synthetic Biology for Therapy
• Chair: Matthew Porteus, Stanford University
• Rachel Haurwitz, Caribou Biosciences
• Kole T. Roybal, Parker Institute
• Ken Drazan, ArsenalBio
In-Vivo Myeloid Programming: Engineering the Innate Immune System for Solid Tumor Therapy
• Daniel Getts, Create Medicines
Synthetic Circuits for Smarter Cell Therapies: Enhancing NK Precision and Persistence
• Gudrun Stengel, Alida Biosciences
